GIÁ TRỊ CHẨN ĐOÁN CỦA HỆ THỐNG PHÂN LOẠI O-RADS ACR 2022 BẰNG SIÊU ÂM KHỐI U BUỒNG TRỨNG ĐƯỢC CHỈ ĐỊNH PHẪU THUẬT

Abstract

Objectives: To evaluate the diagnostic value of the O-RADS ACR 2022 (Ovarian Adnexal Reporting and Data System of the American College of Radiology 2022) in classifying surgically indicated ovarian tumors using ultrasound imaging. Methods: A combined retrospective and prospective, cross-sectional descriptive study was conducted on 182 patients with surgically indicated ovarian tumors at the Central Obstetrics and Gynecology Hospital, admitted from December 2023 to May 2025. Results: Among 182 patients (207 ovarian tumors), the rate of benign tumors was 78.8%, borderline was 4.8%, and malignant was 16.4%. The O-RADS categories 2, 3, 4, and 5 were 38.2%, 28.0%, 21.3%, and 12.5%, respectively. Concordance rate: O-RADS 0 - 3: 100.0% benign tumors; O-RADS 4 - 5: 37.1% benign tumors, 14.3% borderline tumors, 48.6% malignant tumors (p < 0.001). Diagnostic value: The cut-off point was 3.5 (between 3 and 4), AUC = 0.962 (95%CI: 0.940 - 0.985; p < 0.01), with a sensitivity of 100.0% and specificity of 84.0%. Conclusion: The O-RADS ACR 2022 classification system is a reliable diagnostic tool for classifying surgically indicated ovarian tumors. It plays a crucial role in differentiating between benign and malignant tumors, thereby supporting clinicians in determining appropriate treatment strategies.